header logo image


Page 19«..10..18192021..3040..»

Archive for the ‘Gene therapy’ Category

Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa – GlobeNewswire

Tuesday, October 6th, 2020

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Phillip Samayoa, vice president of strategy and portfolio development, will present a company overview at the annual Cell & Gene Meeting on the Mesa. The presentation will be available for registered participants to view on demand throughout the conference, to be held virtually Oct. 12-16, at meetingonthemesa.com.

Geoff McDonough, M.D., Generation Bios president and chief executive officer, will participate in a panel on the future of gene delivery. That discussion will be available to view on demand on the conference website starting Oct. 13.

About Generation Bio

Generation Biois an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The companys non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The companys efficient, scalable manufacturing process supports Generation Bios mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.For more information, please visitgenerationbio.com.

Contact:

InvestorsChelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com910-777-3049

MediaStephanie SimonTenBridge Communicationsstephanie@tenbridgecommunications.com617-581-9333

See the rest here:
Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa - GlobeNewswire

Read More...

Novartis cites ‘transformative’ data on Zolgensma as it rolls out SMA gene therapy in Europe – FiercePharma

Friday, October 2nd, 2020

Nearly five months after snagging a conditional approval for its spinal muscular atrophy (SMA) gene therapy in Europe, Novartis is rolling out fresh data to support a launch that has seen its share of challenges.

The company unveiled interim data from a phase 3 trial of the gene therapy in babies born with the genetic disease. Of the 33 patients treated so far in the European trial, 21 had achieved milestones in motor skills during a mean follow-up period of 10.6 months that the disease would normally prevent, the company said. For example, six could sit without assistance for more than 10 seconds and 20 could control their head movements.

Most of the children in the study who entered it without requiring ventilation remained free of ventilatorsupport, and 67% were able to eat without help, Novartis said during the World Muscle Society 2020 Virtual Congress. Most of the children received a higher score on a widely used test of neuromuscular functioning than untreated SMA patients typically do, the company added.

Developing COVID-19 vaccines may not be enough: Turning vaccines into vaccinations

COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum. What are the steps needed to help ensure the medical supply chain is up to the task?

Shephard Mpofu, M.D., chief medical officer of Novartis Gene Therapies, said in a statement that the data boosts previous clinical trial results supporting the use of Zolgensma in patients with type 1 SMA, the most common form of the disease. With more than 600 patients now treated, including some more than five years post-treatment and more than five years old, these data further reinforce the transformative benefit a one-time dose of Zolgensma has on SMA patients, Mpofu said.

RELATED: New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy

Novartis effort to win approval for Zolgensma in Europe ran into one hurdle back in April 2019, when an infant in the trial died of brain damage and respiratory issues. An autopsy later revealed that the death was unrelated to Zolgensma.

But then, in October of last year, Novartis was hit with questions from regulators in Europe and Japan about the Zolgensma manufacturing process. Resolving the queries from the EU required inspections, and it pushed back thedecision from the EUs Committee for Medicinal Products for Human Use (CHMP).

Now that Zolgensma is finally approved in Europe, though, Novartis has an opportunity to steal market share from Biogens SMA drug Spinraza. Thats because the European approval allows the Zolgensma to be used in children weighing up to 21 kilograms, which basically covers any child under the age of 5.

Thats a significant difference from the FDA approval, which only covers children under 2 years of ageand it could allow Novartis to offer its therapy to older children currently taking Spinraza.

RELATED: Roche touts 2-year Evrysdi data as oral SMA drug drives early interest

Novartis has an ambitious expansion plan for Zolgensma in the U.S., too, though that has hit some obstacles recently. Its working on a new intrathecal formulation of the drug, in the hopes that the FDA will approve that version for children up to 5 years old. But last week, the company said the FDA will require it to run a phase 3 study of the intrathecal formulation, rather than considering it for approval based on a smaller phase 1/2 trial. That could push the filing to 2023.

Analysts deemed the FDAs decision a major setback. Jefferies analysts had estimated the gene therapy would peak at $2.8 billion in worldwide sales, with the intrathecal version claiming $1 billion of that.

Meanwhile, Novartis is facing potential competition from more than just Spinraza. Roche introduced an oral drug for SMA, Evrysdi, last month. And it just revealed new data from a pivotal trial of that drug that intensify Novartis marketing challenge.

In the Evrysdi study, 88% of infants with type 1 SMA were alive without needing full-time ventilation after two years. Their motor functioning also improved in the second year, with more patients able to sit, stand, turn over or maintain head control.

Go here to read the rest:
Novartis cites 'transformative' data on Zolgensma as it rolls out SMA gene therapy in Europe - FiercePharma

Read More...

BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307 -…

Friday, October 2nd, 2020

SAN RAFAEL, Calif., Oct. 2, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in developing treatments for phenylketonuria (PKU) and gene therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation toBMN 307, an investigational gene therapy for the treatment of individuals with PKU.

Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fulfill an unmet medical need, enabling drugs to reach patients earlier. Clinical programs with Fast Track designation may benefit from early and frequent communication with the FDA throughout the regulatory review process. These clinical programs may also be eligible to apply for Accelerated Approval and Priority Review if relevant criteria are met, as well as Rolling Review, which means that completed sections of the Biologic License Application can be submitted for review before the entire FDA application is complete. Both the FDA and European Medicines Agency have granted BMN 307 Orphan Drug Designation.

"Fast Track designation combined with our ability to conduct our clinical studies incorporating material manufactured using a commercial-ready process will further facilitate rapid clinical development of BMN 307 gene therapy," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin. "We are looking forward to working closely with the FDA, as well as other health agencies, to evaluate the safety and efficacy of this promising investigational gene therapy as we continue our unwavering 15-year commitment to advance the standard of care for people with PKU."

PKU is a rare genetic disease that manifests at birth and is marked by an inability to break down Phe, an amino acid that is commonly found in many foods. Left untreated, high levels of Phe become toxic to the brain and may lead to serious neurological and neuropsychological issues, affecting a person's ability to think and problem solve, and can lead to depression, anxiety, and behavior disturbance impacting quality of life. Due to the seriousness of these symptoms, in many countries, infants are screened at birth to ensure early diagnosis and treatment to avoid intellectual disability and other complications. According to treatment guidelines, PKU patients should maintain lifelong control of their Phe levels.

BMN 307 Clinical Program

Last week, BioMarin announced that it had dosed the first participant in the global Phearless Phase 1/2 study with BMN 307, an AAV5-phenylalanine hydroxylase (PAH) gene therapy designed to normalize blood phenylalanine (Phe) concentration levels in patients with PKU by inserting a correct copy of the PAH gene into liver cells. BMN 307 will be evaluated to determine safety and whether a single dose of treatment can restore natural Phe metabolism, increase plasma Phe levels, and enable a normalization of diet in patients with PKU.BioMarin is conducting this study with material manufactured with a commercial-ready process to facilitate rapid clinical development and potentially support approval. BMN 307 represents a potential third PKU treatment option in BioMarin's PKU franchise and a second gene therapy development program.

BioMarin's clinical program is composed of two key studies. Phearless, a Phase 1/2 study, will evaluate the safety, efficacy, and tolerability of a single intravenous administration of BMN 307 in patients with PKU. The study consists of a dose-escalation phase, followed by a cohort expansion phase once an initially efficacious dose has been demonstrated. In addition, BioMarin is sponsoring an observational study, Phenom, which includes patients with PKU to measure both established and new markers of disease and clinical outcomes over time.

BioMarin's 15-Plus Year Commitment to PKU Research

For more than 15 years, BioMarin has been a pioneer in ongoing research to help improve the lives of PKU patients. BioMarin has developed therapies that have been used to treat approximately 7,000 PKU patients around the world. The company has two approved PKU therapies, and the investigational gene therapy BMN 307 is currently in development. BioMarin has conducted 41 clinical studies in PKU and has sponsored 44 external clinical studies. BioMarin researchers have authored 65 publications in medical and scientific journals on PKU and supported another 57 publications by external researchers.

About Gene Therapy

Gene therapy is a form of treatment designed to address a genetic problem by adding a normal copy of the defective gene. The functional gene is inserted into a vector containing a small DNA sequence that acts as a delivery mechanism, providing the ability to deliver the functional gene to targeted cells. The cells can then use the information from the normal gene to build the functional proteins that the body needs, potentially reducing or eliminating the cause of the disease.

Gene Therapy Manufacturing

BioMarin has leveraged its knowledge and experience in manufacturing complex biological products to design, construct and validate a state-of-the-art vector production facility in Novato, California. This facility is the site of production for both valoctocogene roxaparvovec and BMN 307, investigational gene therapies. Manufacturing capabilities are an essential driver for BioMarin's gene therapy programs and allows the Company to control quality, capacity, costs and scheduling enabling rapid development. Production of BMN 307 with a commercial ready process at scale reduces risk associated with making process changes later in development and may speed overall development timelines significantly.

Ongoing process development efforts and experience gained at commercial scale have led to improvements in productivity and operational efficiency. The ability to scale out the facility with additional equipment combined with the improvements in productivity result in a doubling of overall potential capacity to 10,000 doses per year, combined for both products, depending on final dose and product mix. This improvement in productivity is anticipated to meet potential commercial and clinical demand for both valoctocogene roxaparvovec and BMN 307 well into the future.

About Phenylketonuria

PKU, or phenylalanine hydroxylase (PAH) deficiency, is a genetic disorder affecting approximately 70,000 diagnosed patients in the regions of the world where BioMarin operates and is caused by a deficiency of the enzyme PAH. This enzyme is required for the metabolism of Phe, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe intellectual disability, seizures, tremors, behavioral problems and psychiatric symptoms. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all individuals with PKU under the age of 40 in countries with newborn screening programs are diagnosed at birth and treatment is implemented soon after. PKU can be managed with a severe Phe-restricted diet, which is supplemented by low-protein modified foods and Phe-free medical foods; however, it is difficult for most patients to adhere to the life-long strict diet to the extent needed to achieve adequate control of blood Phe levels. Dietary control of Phe in childhood can prevent major developmental neurological toxicities, but poor control of Phe in adolescence and adulthood is associated with a range of neurocognitive disabilities with significant functional impact.

To learn more about PKU and PAH deficiency, please visit http://www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases.The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.For additional information, please visitwww.biomarin.com. Information on such website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the Company's BMN 307 program being eligible to apply for Accelerated Approval and Priority Review if relevant criteria are met, as well as Rolling Review, the development of BioMarin's BMN 307 program generally, including the impact on the timing and process for regulatory interactions and decisions, BioMarin's gene therapy manufacturing capabilities and the anticipation that the current manufacturing capabilities will meet potential commercial and clinical demand for both valoctocogene roxaparvovec and BMN 307 well into the future and the impact of using material manufactured at commercial scale in a clinical trial on reducing risk and speeding up overall development timelines. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others:the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities; uncertainties inherent in research and development, including unfavorable new clinical data and additional analyses of existing clinical data; the results and timing of current and future clinical trials related to BMN 307; our ability to reproducibly and consistently manufacture sufficient quantities of BMN 307, the possibility that changes may be required to the current manufacturing process; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin is a registered trademark of BioMarin Pharmaceutical Inc.

Contacts:

Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

SOURCE BioMarin Pharmaceutical Inc.

https://www.biomarin.com/

See the rest here:
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307 -...

Read More...

Preclinical done right: The importance of using relevant animal models in gene therapy studies – BioPharma Dive

Friday, October 2nd, 2020

Gene therapy is no longer an approach for the future. It's a technique used now.

As of January 2020, the FDA has approved four gene therapies for use in the United States and has received more than 900 investigational new drug (IND) applications for clinical studies. At present, more than 3,400 active gene therapy trials are taking place worldwide, according to ClinicalTrials.gov.

None of these trials would have launched without valid preclinical research. One of the key requirements during preclinical research is selection of the appropriate animal model.

Selecting animal models that reflect the population studied and reproduce the target disease state increases the likelihood that studies will meet strict regulatory expectations. Further, strong preclinical research, with accurate data and clinically relevant biomarkers, helps ensure that clinical trials get to the finish line on time and on budget.

"If you choose a too simplistic model or a model that does not accurately recapitulate the disease state you're trying to address, your preclinical data doesn't amount to much,"said Anjli Venkateswaran, PhD, spokesperson for Biomere, a preclinical CRO based in Worcester, Massachusetts. "Selection becomes even more important in gene therapy research, and it's something scientists grapple with daily."

Gene therapy researchers rely on animal models to assess variables such as safety, efficacy, dosage and localization of transgene expression. Traditional inbred and outbred mice the most common laboratory mice are suitable for most pharmaceutical research. However, when the goal is to alter a human genetic defect, scientists need to test their approach in models that contain the human target sequences. This led to the development of genetically engineered mouse models (GEMMs) of which there are many.

"Any mouse that is genetically changed or altered to be an appropriate model for disease falls under this umbrella,"Dr. Venkateswaran said. "These models express the gene target and recapitulate some, if not all, of the disease pathophysiology."

As animal model providers gain access to next-generation sequencing, genome-engineering tools and other technology, they can develop more customized models. "Older technology was based on homologous recombination,"said Tom Pack, PhD, senior scientist for Axovant, a New York City-based clinical-stage gene therapy company. "Now we've moved into an era of CRISPR-Cas9, where you have more efficient and sophisticated technology for manipulating DNA, and you can more closely mimic human mutations. You can also focus on specific organs or tissue types with DNA recombinase-based and intersectional genetics approaches to design more targeted therapies more rapidly."

For all the technological advances, certain studies may require a different type of model. "There are limitations as to how much you can humanize mice,"Dr. Venkateswaran said. "Also, mice behave very differently physiologically from humans, and they have a different blood-brain barrier, which can result in differences in gene therapy delivery to the brain. Because of their anatomical differences, large-animal models are emerging in gene therapy."

Large-animal models, including nonhuman primates, may suit certain studies more specifically than humanized mice. For example, pig models have been used effectively in cystic fibrosis studies because their respiratory is more similar to humans than mouse models.

However, large-animal models have limitations. They are more expensive than mouse models and require specialized scientists and technicians and adequate lab space. That's why Dr. Venkateswaran recommends that, generally, researchers should start small and move up.

"You need to get some confidence in your gene therapy's performance,"she said. "When data looks good in in vitro models and in mouse models, then, depending on the therapy, consider testing in relevant large animal models."

Axovant has two pediatric rare-disease studies in the pipeline: both fatal diseases with no other treatment options available. These delicate situations require Axovant to be especially thoughtful about model selection.

"You not only want to mimic the genetic condition, you want to be able to practice the same surgical techniques you would use to deliver the therapy as well as look at some of the same clinical biomarkers,"Dr. Pack said. "With a larger-animal model, you can optimize everything clinically before you start clinical trials."

To determine the appropriate animal model(s) for preclinical gene therapy studies, researchers must weigh both scientific and practical considerations.

Scientific considerations include:

Practical considerations include:

Gene therapy researchers have a lot to consider when designing preclinical research. Appropriate animal model selection is one of the first and most important steps to help move that research into clinical trials.

Fortunately, a select group of CROs have preclinical research expertise to help expedite the process. That includes access to complex genetically modified mouse models and other animal models, as well as scientific experts that understand the biology of these models. Many CROs, including Biomere, also have housing and breeding programs and experience with testing multiple types of therapies (CRISPR-mediated gene editing, AAV and other viruses, RNA therapeutics (RNAi andmiRNA), ceDNA, antisense oligos etc.).

"When you get it right in preclinical studies, you improve the success rate in the clinic,"Dr. Venkateswaran said. "A more thoughtful approach will lead to more robust therapies, which ultimately leads to more patient lives saved." To learn more about model selection for gene therapy studies, download Biomere's white paper.

Need a preclinical partner for a gene therapy study? Visit Biomere.com to contact one of its scientists about your preclinical study today.

Meyerholz DK. Lessons learned from the cystic fibrosis pig.Theriogenology. 2016;86(1):427-432. doi:10.1016/j.theriogenology.2016.04.057

More:
Preclinical done right: The importance of using relevant animal models in gene therapy studies - BioPharma Dive

Read More...

Gene Therapy Stocks Continue To Underperform. Are They Worth A Look? – Forbes

Friday, October 2nd, 2020

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patients cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interest in the sector appears to have died down considerably, on account of high R&D spending and delays companies have seen in launching revenue-generating products. Our indicative theme of Gene-Based Therapy Stocks is down by about -23% year-to-date, underperforming the S&P 500 which is up by about 2%. However, with valuations declining, these companies could be attractive bets for investors as years of investments potentially start to pay off. These companies could also be acquisition candidates for big pharma. Below is a bit more about these companies and how they have fared this year.

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that develops RNA-targeted therapeutics and gene therapy products. The company recently provided some positive data on its investigational gene therapy for Duchenne muscular dystrophy. The stock is up 11% year-to-date.

SRPT

Voyager Therapeutics is a clinical-stage biotech company that is developing gene therapies for Parkinsons disease, Huntingtons disease, and other conditions. The stock is down by about -20% year-to-date.

REGENXBIO Inc.: is a clinical-stage biotechnology company working on gene-based therapies for Retinal diseases, Hunter and Hurler syndromes. The stock is down by about -33% this year.

uniQure is primarily focused on gene-based therapy for Hemophilia and is currently in the late-stage of clinical trials and another program focuses on Huntingtons disease. The stock is down by about -49% year-to-date.

What if youre looking for a more balanced portfolio instead? Heres a high-quality portfolio to beat the market, with over 100% return since 2016, versus 50% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.

See allTrefis Price EstimatesandDownloadTrefis Datahere

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams |Product, R&D, and Marketing Teams

See the article here:
Gene Therapy Stocks Continue To Underperform. Are They Worth A Look? - Forbes

Read More...

Sareptas First Gene-Therapy Test Patients Look Good, 2 Years Out – Barron’s

Friday, October 2nd, 2020

Text size

A question hanging over gene therapies, which attempt a once-and-done fix for genetic diseases, is will their benefits endure? Monday, Sarepta Therapeutics told a scientific conference that the first four children who got its investigational gene therapy, for Duchenne muscular dystrophy, all continued to show better-functioning muscles after two years.

Durability is an important consideration for a onetime treatment, said Sareptas head of gene therapy, Louise Rodino-Klapac. She spoke on a conference call, part of an online version of the annual congress of the World Muscle Society, where scientists reported their progress against the often-deadly muscular dystrophies.

Sarepta (ticker: SRPT) said that a battery of tests that measure daily functions like walking and fatigue showed the children doing even better than they had at the one-year mark. The assessment is an average of 17 tests, and not every child showed improvement on every measure.

Perhaps that is why Sarepta stock slipped 0.5% on the day, to $143.20, in a rising stock market.

Analysts may have also been anxious to hear whether Sarepta had resolved questions raised by the U.S. Food and Drug Administration about the production process to be used in a Phase 3 study of the gene therapy. Agency demands have slowed the timetables of other gene- therapy developers, and its questions for Sarepta are delaying the launch of its pivotal trial.

Chief executive Doug Ingram said Sarepta was ready with a process to produce therapies for a clinical trial and subsequent commercial demand. Were working with the agency right now to resolve any questions that they might have, said Ingram, get their blessing and be starting that trial as soon as is possible.

RBC Capital analyst Brian Abrahams found the data encouraging. He rates Sarepta stock at Outperform, with a price target of $200 a share.

We view the results as continuing to support true functional benefits from the companys gene therapies, Abrahams said in a Monday note. These studies werent controlled, he cautioned, so investors are looking forward to Sareptas results from a randomized, controlled study for which results should be available in the first quarter of 2021.

On Sareptas heels is Pfizer (PFE), with clinical trials of a gene therapy for muscular dystrophy whose benefits it has measured out to one year.

At the conference, Sarepta also showed data from early-stage trials of a gene therapy for another group of inherited muscle diseases, known as Limb-girdle muscular dystrophies. Functional tests of the first three patients showed them maintaining their improvement over 18 months.

CEO Ingram reminded the audienceand perhaps any listening regulatorsthat families are impatient for these muscular dystrophy trials conclusions.

This is truly -- Im not being hyperbolic, but I say in a very real sense, at least from our perspective, a matter of life and death, he said. We have to get this trial started. Kids are waiting for this therapy.

Write to Bill Alpert at william.alpert@barrons.com

The rest is here:
Sareptas First Gene-Therapy Test Patients Look Good, 2 Years Out - Barron's

Read More...

CRB’s SlateXpace gives cell and gene therapy clients new flexibility, control over manufacturing needs to support highly complex product pipelines -…

Friday, October 2nd, 2020

SlateXpace (pronounced "Slate Space") is a CRB solution that breaks from conventional facility design by providing unparalleled flexibility, speed to market and budget control, allowing companies to quickly deliver multiple novel therapies to patients. Clients get a customizable, time and cost-efficient solution that accommodates rapidly evolving multi-modal pipelines while future-proofing their capital investments. They also get peace of mind as SlateXpace leverages the expertise and capabilities of a team that manages every detail end to end from facility fabrication and delivery, equipment selection and installation, to start-up, qualification and operator training.

The agility at the heart of SlateXpace's mission heralds a critical turning point in the story of advanced therapy medicinal product (ATMP) manufacturing. The 1980s biotech explosion, the advent of stainless-steel facilities, and the arrival of closed processing technology and eventually ballroom manufacturing concepts each ushered periods of uncomfortable adjustment followed soon by untapped potential. Today, biotechnology companies are navigating the next scientific breakthrough with the promises brought on by the rise of cell and gene therapy products. However, many operators remain constrained by technologies and processes ill-suited for a fast-shifting market.

SlateXpace seizes on that potential by giving clients full operational turnkey delivery, upfront cost and schedule confidence and infinite flexibility, allowing clients to capture new markets or take advantage of emerging technologies. Implementing SlateXpace facilities allows you to constantly transform and grow with your business to address rapidly evolving market demands.

Drawing on CRB's more than 35 years of life sciences experience, SlateXpace's unique suite-based platform moves ATMP manufacturing beyond off-the-shelf cleanroom boxes and into a new era that empowers clients to shift flexibly, quickly and seamlessly between therapies. Using SlateXpace, an operator could run a product campaign in one modality, decontaminate that space, swap out single-use and mobile equipment and run a new batch in the same space in a different modality all within a few weeks.

Modalities currently test-fitted for SlateXpace include vaccines, monoclonal antibodies (mAbs), viral vectors, plasmids, allogeneic cell therapies and autologous cell therapies as well as the potential to accommodate other future biotech modalities an "X" factor that can accommodate bespoke client designs, new technologies or unforeseen scientific breakthroughs.

"SlateXpace meets the market need for a truly essential and efficient facility design, one that makes many, highly-tailored processes possible for clients," said Ryan Schroeder, President of CRB. "We started SlateXpace with the goal of delivering a facility that would never be idle. Manufacturers have the means to rapidly shift their operations as technologies change, business expands, and patient needs evolve. That will minimize downtime and maximize growth, no matter what comes next."

"Whether it's an established biotech company or contract manufacturing organization (CMO) looking for maximum operational flexibility to support complex product combinations across their global network, or a startup company looking for scalability and cost control so they can focus on development, SlateXpace provides a holistic solution with unparalleled advantages over today's manufacturing environments" said Noel Maestre, Director of SlateXpace based in San Diego. "The term 'disruptive' gets thrown around a lot in our industry. But for our clients, SlateXpace is exactly that a game-changing turnkey facility that delivers the kind of flexibility once considered impossible for customized and novel processes."

To learn more about SlateXpace and how CRB can provide your business a future-proof facility beating all industry benchmarks for speed, flexibility and adaptability visit our website at http://www.slatexpace.com. We can also be found on LinkedInand Twitter.

About SlateXpace:

SlateXpaceTM (pronounced "Slate Space"), is a CRB forward-looking solution that provides configurable and equipment-agnostic facilities to the ever-adapting life sciences industry. It allows clients to rapidly shift operations as technologies, business objectives, and patient needs evolve. Find us at http://www.slatexpace.com and on social media.

About CRB:

CRB is a leading provider of sustainable engineering, architecture, construction and consulting solutions to the global life sciences and advanced technology industries. Our more than 1,300 employees provide best-in-class solutions that drive success and positive change for our clients, our people and our communities. CRB is a privately held company with a rich history of serving clients throughout the world, consistently striving for the highest standard of technical knowledge, creativity and execution.

MEDIA CONTACT INFORMATION:Chris Clark: 816-200-5234

SOURCE CRB

http://www.crbusa.com

Original post:
CRB's SlateXpace gives cell and gene therapy clients new flexibility, control over manufacturing needs to support highly complex product pipelines -...

Read More...

FDA Grants Fast Track Designation to Pfizer’s DMD Gene Therapy – BioSpace

Friday, October 2nd, 2020

Pfizer snagged Fast Track designation from the U.S. Food and Drug Administration (FDA) for its Duchenne muscular dystrophy (DMD) gene therapy treatment, PF-06939926.

PF-06939926 is currently being evaluated to determine its safety and efficacy in boys with DMD. In May, the company reported promising preliminary results from a Phase Ib study of the gene therapy asset. Data from nine boys with DMD between the ages of six and 12 showed encouraging efficacy and manageable safety events, Pfizer said. As BioSpace reported at the time, PF-06939926 demonstrated durable and statistically significant improvements in multiple efficacy endpoints measured 12 months following infusion. These included sustained levels of mini-dystrophin expression and improvements on the North Star Ambulatory Assessment (NSAA) rating scale.

Although the efficacy is promising, there were three serious adverse events in the study. Two appeared to be immune reactions related to complement activation. While they were severe, all three events were fully resolved within two weeks.

DMD causes a progressive loss of muscle strength attributable to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down. Approximately 15,000 U.S. patients are affected with DMD, with a total of about 300,000 patients worldwide.

The Fast Track designation awarded by the FDA was based on data from that Phase Ib study. With the designation, Pfizer will be able to have an expedited review of PF-06939926 when, and if, it is submitted for potential regulatory approval.

The FDAs decision to grant our investigational gene therapy PF-06939926 Fast Track designation underscores the urgency to address a significant unmet treatment need for Duchenne muscular dystrophy, Brenda Cooperstone, Chief Development Officer of Rare Disease at Pfizer Global Product Development said in a statement. DMD is a devastating condition and patients, and their parents, are waiting desperately for treatment options. We are working to advance our planned Phase 3 program as quickly as possible.

PF-06939926 is an investigational, recombinant adeno-associated virus serotype 9 (rAAV9) capsid carrying a shortened version of the human dystrophin gene (mini-dystrophin) under the control of a human muscle-specific promotor. The rAAV9 capsid was chosen as the delivery vector because of its potential to target muscle tissue, Pfizer said.

Pfizer announced the Fast Track designation the same day Solid Biosciences announced the FDA lifted a nearly year-long clinical hold on its gene therapy treatment for DMD, SGT-001. The treatment delivers microdystrophin, a synthetic dystrophin gene, which encodes for a functional protein surrogate that is expressed in muscles and stabilizes essential associated proteins.

Currently, there are two FDA-approved DMD treatments. Sarepta Therapeutics Exondys 51 was approved in 2016 for DMD patients amenable to skipping exon 51. Last year, Sarepta secured another FDA approval for Vyondys 53, which was greenlit for patients amenable to skipping exon 53.

See more here:
FDA Grants Fast Track Designation to Pfizer's DMD Gene Therapy - BioSpace

Read More...

Gene therapy solution: The value of a CDMO as your end-to-end partner – BioPharma Dive

Friday, October 2nd, 2020

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past few years. At present, ClinicalTrials.gov shows more than 4,500 active gene therapy trials globally. In the United States, McKinsey experts expect to see 10 to 20 cell and gene therapy approvals per year over the next five years.

This rise in supply has created a heightened demand for contract development and manufacturing organizations (CDMOs) with biotech expertise. CDMOs typically supply materials and handle production and manufacturing, allowing life sciences companies to focus on innovation and marketing.

The bottleneck stems from a shortage of CDMOs with gene therapy expertise and resources. Considering the critical need for safe, effective gene therapies and the rapid pace of development, it's important for pharma and biopharma to find a CDMO with both gene therapy capabilities and availability to take on new partners nownot 18 months from now.

"Full-service CDMOs that can assist with both development and manufacturing are in highest demand,"said Richard Welch, PhD, vice president, development services for Emergent BioSolutions, a global CDMO and specialty life sciences company headquartered in Gaithersburg, Maryland. "As pharma and biopharma companies move from early phase to late phase, CDMOs need experience with process characterization and process validation as well as commercial production and supply chain."

"The supply chain is much more complex,"added Tarek Abdel-Gawad, senior director of commercial strategy for Emergent BioSolutions. "You aren't just growing cells. You're ensuring viruses, helper viruses, and plasmid DNA work together to produce the molecule of choice. Few companies have the capabilities, equipment, and GMP expertise."

Much of the gene therapy development as of late has stemmed from smaller biotech companies or research universities according to a McKinsey report. Large pharmaceutical companies may partner with these organizations on rare disease or oncology treatments two therapeutic areas where much of the research lies.

Many small to midsize companies have the idea and investor support, but do not have the employees, infrastructure or manufacturing space. "A CDMO is a good partner in those cases,"said Mukesh Mayani, PhD, principal scientist, gene therapy at Sanofi. "You can test your hypotheses and work with a CDMO that has the platform, the people, and the preclinical models. This arrangement speeds up the timeline and allows these innovative companies to focus on other modalities and molecules."

Pharma and biopharma companies of all sizes can learn from this "single-source"approach. Partnering with a CDMO earlier in the processfrom preclinical development through packagingfrees up resources to focus on innovation and communication.

"It is neither simple nor cheap to develop and manufacture gene therapies,"said Dr. Welch. "A CDMO has the built-in skill set to grow viruses at the densities necessary to meet early-phase studies while hitting safety margins. With the clinical trial failure rate as high as it is, working with a CDMO that has experience in different technologies and products makes for a more efficient, cost-effective process."

Although there is a high demand now for CDMOs with gene therapy expertise, the market is quickly growing. According to Grand View Research, the CDMO market is expected to grow from $115.6 billion in 2020 to $157.7 billion in 2025, outpacing the pharmaceutical industry as a whole. New cell and gene therapy CDMOs are emerging and established CDMOs are expanding capabilities.

Before you start your CDMO search, consider the following two factors:

When vetting CDMOs for your gene therapy studies, consider the strengths and weaknesses of your company as well as your potential CDMO partner. A few points to consider include:

As gene therapy research continues to expand, innovators in this space will need CDMOs with highly specific expertise, facilities, and equipment. Choose a partner that can assist from the earliest phases of product development all the way to commercialization.

Capra, Emily, et al. "Gene therapy coming of age: Opportunities and challenges to getting ahead."McKinsey, October 2, 2019

Continue reading here:
Gene therapy solution: The value of a CDMO as your end-to-end partner - BioPharma Dive

Read More...

BioLife Solutions Closes Acquisition of SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry – PRNewswire

Friday, October 2nd, 2020

BOTHELL, Wash., Oct. 1, 2020 /PRNewswire/ --BioLife Solutions, Inc. (NASDAQ: BLFS)("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has closed the acquisition of SciSafe, a privately held multi-facility provider of biological materials storage to the cell and gene therapy and pharmaceutical industries.

SciSafe had 2019 unaudited revenue of $6 million and positive EBITDA and is anticipated to be accretive during 2021. Fourth quarter 2020 revenue is estimated at$1.8 million.

About SciSafe

Founded in 2010, SciSafe offers dedicated pharmaceutical and biological specimen storage in its four fully cGMP-compliant state-of-the-art sample management facilities. SciSafe has built flourishing relationships with over 300 of the world's leading and most admired organizations. Clients have repeatedly chosen to store their most valued and irreplaceable biological samples because they trust SciSafe to care for them as if they were their own. SciSafe values and respects its long-term client relationships. With over 60 years combined experience specifically in life sciences, SciSafe personnel fully appreciate the vital requirements of all areas of specimen storage and cold chain management. For more information, please visit http://www.scisafe.com.

About BioLife Solutions

BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietaryCryoStorfreeze media and HypoThermosolshipping and storage media, ThawSTARfamily of automated, water-free thawing products, evocold chain management system, and Custom Biogenic Systemshigh capacity storage freezers. Services include SciSafe biologic and pharmaceutical materials storage. For more information, please visit http://www.biolifesolutions.com, and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its acquisition of SciSafe, the expected synergies between the company and SciSafe, the company's ability to realize all or any of the anticipated benefits associated with the acquisition of SciSafe, the company's ability to implement its business strategy and anticipated business and operations, including following the acquisition of SciSafe, the potential utility of and market for the company's and SciSafe's products and services, guidance for financial results for 2020 and 2021, including regarding SciSafe's revenue, and potential revenue growth and market expansion, including with consideration to our acquisition of SciSafe. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding unexpected costs, charges or expenses resulting from the company's acquisition of SciSafe or the 2019 acquisitions, charges or expenses resulting from the acquisition of SciSafe; market adoption of the company's products (including the company's recently acquired products) or SciSafe's products; the ability of the SciSafe acquisition to be accretive on the company's financial results; the ability of the company to implement its business strategy; uncertainty regarding third-party market projections; market volatility; competition; litigation; the impact of the COVID-19 pandemic; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations

Roderick de Greef

Chief Financial Officer

(425) 686-6002

[emailprotected]

SOURCE BioLife Solutions, Inc.

http://www.biolifesolutions.com

More here:
BioLife Solutions Closes Acquisition of SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry - PRNewswire

Read More...

Fujifilm Diosynth Biotechnologies’ Advanced Therapies Innovation Centre – pharmaceutical-technology.com

Friday, October 2nd, 2020

The Advanced Therapies Innovation Centre will be located in College Station, Texas, US. Credit: FUJIFILM Diosynth Biotechnologies. The new centre will house dedicated process development and innovation laboratories. Credit: Gorodenkoff/Shutterstock. The Advanced Therapies Innovation Centre is scheduled to be operational by fall 2021. Credit: CI Photos/Shutterstock.

Fujifilm Diosynth Biotechnologies (FDB) began the construction of its Advanced Therapies Innovation Centre in College Station, Texas, US.

The facility will triple the FDBs gene therapy development capabilities with the addition of dedicated process and analytical development laboratories. It will support the manufacturing of Covid-19 vaccine under the Operation Warp Speed, a US governments initiative to begin delivery of safe and effective Covid-19 vaccine in the US.

The $55m Advanced Therapies Innovation Centre is a part of the Fujifilms plan announced in November 2019 to invest $120m (13bn) in gene therapy.

FDB held a virtual groundbreaking ceremony for the facility in August 2020. The facility should be operational by fall 2021 and will add approximately 100 jobs to the Texas campus.

Advanced Therapies Innovation Centre is being constructed adjacent to the Flexible Biomanufacturing Facility (FBF), FDBs existing state-of-the-art cGMP gene therapy manufacturing facility in College Station, Texas, US.

The building will occupy an area of 60,000ft2 and be a part of a 22-acre land acquired from Lake Walk by FDB in June 2020. The facility will be equipped with multiple 500L and 2000L bioreactors. It will house designated laboratories with BSL-2 capabilities including state-of-the-art technologies for upstream, downstream and analytical development.

Gene Therapy Innovation Centre will help customers create gene therapy drugs for the treatment of genetic disorders such as cancer and muscular dystrophy.

FDF was subcontracted for the manufacturing of Covid-19 vaccine candidate by Centre for Innovation in Advanced Development & Manufacturing (CIADM) under the task order issued by the US Biomedical Advanced Research and Development Authority (BARDA) in July 2020.

Expansion of the Texas facility will enhance vaccine production at the campus. The transfer of technologies from North Carolina to Texas for the mass production of NVX-CoV2373, Novavax Covid-19 vaccine candidate, will start at the end of 2020 with the mass production beginning in early 2021.

State-of-the-art facilities of the FDB include over 50 bioreactors ranging from 3l to 200l and support technologies such as Cyto-Mine and ambr 250 screening for both flexibility and capacity.

FDB offers both single-use (200l-2,000l) and stainless steel (20,000l) manufacturing platforms, cell culture systems, QdB, process transfer-in and development process monitoring in upstream and resin screening, UF or DF development, process characterisation, intermediate stability, pegylation, hapten conjugation and enzymatic cleavage in downstream.

Expansion of the Texas facility will enhance vaccine production at the campus.

The new UV-vis spectroscopy technology, SoloVPE, is utilised to deliver precise measures of concentration in less than a minute. It allows less time spent on in-process processing and more time spent producing the product.

The technology uses calculations of variable-path length to define the linear absorbance spectrum that is connected to the path length.

FDB is a contract development and manufacturing organisation (CDMO) with offices in College Station and Research Triangle Park in the US, Teesside in the UK, and Hillerod in Denmark. It focusses on the development and manufacturing of microbial, mammalian, and viral therapies, gene therapy and vaccines.

Core FDB services include process development, analytical development and current good manufacturing practice (cGMP) manufacturing.

The company offers an extensive list of premium services including process development, cell-line development, analytical development, clinical and FDA-approved commercial manufacturing, using its proprietary microbial pAVEway microbial and Apollo cell line systems technologies.

Read the original post:
Fujifilm Diosynth Biotechnologies' Advanced Therapies Innovation Centre - pharmaceutical-technology.com

Read More...

Risk Based Therapy Approach for Sickle Cell Anemia Patients is Ideal Scenario – MD Magazine

Friday, October 2nd, 2020

Although the therapeutic options for sickle cell anemia have expanded over the past years, the clinical complications of the condition as well as the limitations of these pharmacotherapies have called for an urgent need to implement a personalized treatment strategy for patients that is based on risk stratification.

In a recent article, Emily Meier, MD, of the Indiana Hemophilia and Thrombosis Center, elucidated on the key considerations in the prescribing of such therapies as well as the current barriers that preclude healthcare providers from achieving an optimal treatment strategy for these patients.

With increasing therapeutic options, the ideal scenario for children with SCA would be one similar to childhood acute lymphoblastic leukemia (ALL) risk stratification: treatment intensity varies with risk level, Meier wrote.

Thus, children who are at low risk for sickle cell anemia complications would receive less intense therapies, which includes a continuation of hydroxyurea. On the other hand, those with the highest risk would be recommended to immediately receive one or more curative therapies, such as hematopoietic stem cell transplant, gene therapy, transfusion therapy, voxelotor, and/or crizanlizumab.

Of course, as Meier noted, there are certain limitations that must be considered before implementing such a strategy.

For one, crizanlizumab and voxelotor are approved for ages 16 and 12 years, respectively. According to the risk based therapy model, high-risk patients should only use both therapies once age appropriate.

Similarly, patients with medium risk of complications should only use L-glutamine once they reach the appropriate age of 5 years.

Additionally, there is no validated predictor for the overall severity of the disease prior to the onset of associated complications. Currently available predictors of a severe outcome is an abnormal velocity on transcranial Doppler ultrasonography. These predictors identity children at highest risk for stroke.

Meier noted that there are no predictors for vaso-occlusive episodes or acute chest syndrome.

Furthermore, there is no unanimous agreement of what constitutes severe sickle cell anemia. However, the inclusion criteria for hematopoietic stem cell transplant is considered a promising start.

Overall, Meier suggested that hydroxyurea should be the standard of care in pediatric and adult patients, regardless of disease severity.

In adults with sickle cell anemia, a risk-based strategy should still be utilized, but the end organ injury makes such an approach more challenging to implement.

She suggested that the additional FDA-approved treatments should be based on clinical and laboratory complications that are still present even after hydroxyurea dosing has been maximized.

According to the seminal trials in support of these agents, L-glutamine and crizanlizumab should be considered as additional therapy in patients who continue to experience vaso-occlusive episodes. Meier also encouraged the addition of voxelotor to hydroxyurea for those adults who continue to have significant anemia.

Hopefully, as the number of SCA modifying and curative therapies increase, more innovative treatment strategies will be tested and lead to improved quality of life and increased life expectancy for individuals with SCA, she concluded.

The opinion piece, What are the key considerations when prescribing pharmacotherapy for sickle cell anemia? was published online at Taylor & Francis Online.

Originally posted here:
Risk Based Therapy Approach for Sickle Cell Anemia Patients is Ideal Scenario - MD Magazine

Read More...

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference – GlobeNewswire

Friday, October 2nd, 2020

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneider, Chief Technology Officer and Cathryn Clary, Interim Chief Medical Officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Tuesday, October 6, 2020 at 4:45 pm ET.

A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.

About Solid BiosciencesSolid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visitwww.solidbio.com.

Investor Contact:David CareyFINN Partners212-867-1768David.Carey@finnpartners.com

Media Contact:Erich SandovalFINN Partners917-497-2867Erich.Sandoval@finnpartners.com

Here is the original post:
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference - GlobeNewswire

Read More...

Gene Therapy Market 2020 by Top Manufacturers, Growth, Trends, Size, Share, Analysis and Forecast to 2030 – The Daily Chronicle

Friday, October 2nd, 2020

Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industrys evolution and identifying potential future growth opportunities.

Key Inclusions

For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Key therapeutic areas

Type of vector

Type of therapy

Type of gene modification

Route of administration

Key geographical regions

The report includes detailed transcripts of discussions held with the following experts:

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

Read more from the original source:
Gene Therapy Market 2020 by Top Manufacturers, Growth, Trends, Size, Share, Analysis and Forecast to 2030 - The Daily Chronicle

Read More...

Cell and Gene Therapy Technology Update: ReNeuron Presents Positive Data | Roots Analysis – Crypto Daily

Friday, October 2nd, 2020

ReNeuron, the UK based, clinical-stage stem cell therapeutics company, announced that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT).

Get a complete list of the presentations,here.

Dr. Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the companys proprietary, conditionally immortalized, human neural stem cell line (CTX) following re-programming to a pluripotent state. The new data being presented today show for the first time that these CTX-iPSCs (induced pluripotent stem cells) can indeed be differentiated along different cell lineages to generate, for example, mesenchymal stem cell lines.

Further, the mesenchymal stem cell lines generated can be grown at scale by virtue of the companys conditional immortalization technology, enabling the efficient production of clinical-grade cell therapy candidates.

Cell and Gene Therapy Market:

Cell and gene therapies have garnered a lot of traction from several big pharma players and new drug developers in recent years. In fact, as per the Alliance of Regenerative Medicines recent findings, there has been more than 75% year on year increment in funding to support the development of various cell and gene therapies. With over 2,600 clinical trials registered to date, cell and gene therapies are playing in a league of their own.

For further information, check out the report here

Read more insights at

Roots Analysis Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

Read the original:
Cell and Gene Therapy Technology Update: ReNeuron Presents Positive Data | Roots Analysis - Crypto Daily

Read More...

Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy – The Scientist

Saturday, September 26th, 2020

A little more than a decade ago, seven patients with hemophilia Ba disease caused by a mutation on the F9 gene that prevents patients from forming crucial clotting proteinsvolunteered to be the first humans to receive a gene therapy delivered using an adeno-associated virus as a vector. This particular treatment didnt move past the Phase 1/2 trial because, while it was deemed safe, the patients did not sustain expression of the gene. But two other gene therapies based on an adeno-associated virus (AAV), Luxturna for rare forms of blindness and Zolgensma for spinal muscular atrophy, have since been approved by the US Food and Drug Administration (FDA), and several pharmaceutical companies are now pursuing regulatory approval of AAV-carried gene therapies for hemophilia B.

Recently, scientists followed up with four of those original patients. In a study published in Molecular Therapy in September, they report that the men are still free of any worrisome toxicities related to the treatment. The study wasnt all good news, though. The team also found that after all these years, the men still had elevated levels of AAV-neutralizing antibodies. That means that if an AAV gene therapy is approved to treat their illness, they likely wont be able to benefit from itthe antibodies would chew up the vector before it could insert the corrective gene.

Administration of an AAV gene therapy is essentially a vaccine against AAV, says Lindsey George, a hematologist at the Childrens Hospital of Philadelphia who led the research. Hers was not the first study to identify antibodies as a problem for those receiving AAV gene therapies, but it is the first to show that elevated titers can last this long. This role of AAV neutralizing antibodies is huge, says George, as it stands to undermine the effectiveness of gene therapies.

Because AAVs are viruses, the human immune system creates antibodies upon exposure that recognize and neutralize them in subsequent encounters. Sometimes patients have neutralizing antibodies in their blood before ever having received a gene therapy because theyre exposed to AAVs in the environment.

The ability to effectively modulate the antibody-mediated immune response could make AAV gene therapies far more effective for far more patients than they are now.

Along with high levels of antibodies to the specific AAV vector that theyd receivedAAV2the patients Georges team evaluated also had neutralizing antibodies to several other commonly used AAV vectors, namely, AAV5 and AAV8, she tells The Scientist.

Andrew Davidoff, a pediatric surgeon at St. Jude Childrens Research Hospital who studies AAV gene therapies but was not involved in the study, says, This paper suggests that not only will they not be able to receive a second dose of vector of the same [type of AAV], but potentially even other [types].

If scientists can prevent antibodies from neutralizing the AAV, they would not only give patients like these another opportunity to receive a more effective dose of gene therapy, but it will expand the patients that we can treat with the therapy to include the 3050 percent of patients who have already been exposed to AAVs in the environment, says Giuseppe Ronzitti, who heads a lab focused on gene therapy research at Genethon.

But, Davidoff says, nobody has found a suitable solution yet that is likely to be accepted by patients. The body has evolved over millions of years, this immune system that helps fight off infections. So to overcome that, even temporarily, is not an easy task.

Some immunosuppressant drugs wont work if the body has already developed specific antibodies to a particular pathogen, such as AAV. Scientists are therefore testing combinations of different types of immunosuppressants they hope will prevent the body from attacking AAVs, but these are likely to come with major risks, chiefly, susceptibility to infection.

Another option is plasmapheresisa process in which a persons blood is removed from the body and the cells separated from the plasma so that they can be reinfused without the antibodies found in the plasmabut, like immunosuppressant drugs, the technique is nonspecific and comes with similar risks. Its a matter of risk-benefit with the continued immunosuppression, says Ronzitti.

So scientists have been looking for other ways to control the bodys response to these gene therapy vectors.

Ronzitti and his team recently proposed a solution in Nature Medicine. The scientists used the imlifidase (IdeS) protein, conditionally approved by the European Commission, to degrade immunoglobulin G (IgG) antibodies that are developed after the body encounters a specific antigen so that it can remember and target that antigen in the future, and thus might cause a patient to reject a transplanted kidney. IgG antibodies are responsible for the immune systems response to AAVs. Its a newer, less invasive alternative to plasmapheresis, Ronzitti tells The Scientist in an email.

The team injected monkeys with the IdeS protein before administering a dose of gene therapy targeting the liver. The treatment appeared safe, the monkeys levels of preexisting AAV antibodies went down, and the AAV vector successfully made its way to the liver. To model a scenario in which a patient would need more than one dose of gene therapy, the scientists administered an AAV gene therapy to another group of monkeys before giving them the IdeS protein to degrade the antibodies theyd developed in response, then readministered the gene therapy. Again, AAV antibodies diminished after the IdeS treatment and the second gene therapy dose was successfully delivered.

One drawback to the approach is that IgGs are the most prevalent type of antibody found in the blood, and destroying all of them may have undesirable side effects. In an attempt to develop a more targeted therapy, one group published a study in January demonstrating that a specialized version of plasmapheresis could reduce the levels of antibodies against human AAVs in mice to the point where a new gene therapy should be effective, without depleting all other immunoglobulins that formed in response to infections.

More recently, a team of researchers at the University of Pittsburgh Medical Center made use of CRISPR-Cas9 to increase the efficacy of AAV gene therapy in mice. Pathologist Samira Kiani and her team werent looking for ways to improve gene therapy, but instead were seeking to temporarily modulate immunity in hopes of changing the course of diseases such as septicemia, a precursor to sepsis that occurs when an infection makes its way to the blood. The researchers aimed to temporarily downregulate the Myeloid differentiation primary response 88(Myd88) gene, which would briefly dampen the immune response, and then remove the brakes.

The gene that we chose to target is known to a be a central gene for innate and adaptive immunity, says Kiani. It controls the production of IgG antibodies in response to AAV exposure, which provided a simple way to measure whether the strategy was effective. If the team administered an AAV to an animal shortly after it had received the CRISPR-Cas9 treatment, it should have a substantially lower antibody response to the virus.

First, they administered the CRISPR to tamp down Myd88 activity and measured a reduction in the expression of the Myd88 gene, as theyd expected. Then, the team used the technique to treat mice just before giving them a dose of AAV-based gene therapy that was designed to lower their cholesterol.

Weeks later, the researchers administered a second dose of the same AAV vector to determine if the temporary immunosuppression during the first dose had prevented the mice from making enough antibodies to thwart a second dose. The mice that were pretreated with the immune-modulating CRISPR showed lower levels of AAV-neutralizing antibodies and more dramatic responses to the cholesterol-lowering AAV treatment. The study was published in NatureCell Biologyin September.

If given prior to the administration of an AAV gene therapy, this approach would prevent the formation of new antibodies, so the patient could receive a second dose later, if needed, says Kiani. Given that the CRISPR treatment only prevents the development of antibodies temporarily, it shouldnt cause any long-term suppression of the rest of the immune system. On the flip side, because it doesnt clear existing antibodies, if the patients have already pre-existing antibodies [from natural exposure] this approach might not be the best approach.

All of the potential solutions have a long way to go, including still needing to be tested in human patients, but the ability to effectively modulate the antibody-mediated immune response could make AAV gene therapies far more effective for far more patients than they are now, says Ronzitti. The immune response to these vectors is quite a complex story, he says. But we are solving the issues one by one.

L. George et al., Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B,Molecular Therapy,doi:10.1016/j.ymthe.2020.06.001, 2020.

F. Moghadam et al., Synthetic immunomodulation with a CRISPR super-repressor in vivo,Nature Cell Biology,doi:10.1038/s41556-020-0563-3, 2020.

Read more here:
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy - The Scientist

Read More...

BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy | DNA…

Saturday, September 26th, 2020

DetailsCategory: DNA RNA and CellsPublished on Friday, 25 September 2020 11:15Hits: 398

BioMarin Builds Upon 15+ Year Commitment to PKU Community with Potential 3rd Therapy in PKU Franchise

Company Leverages Gene Therapy Manufacturing Expertise Using Commercial-Ready Process

SAN RAFAEL, CA, USA I September 24, 2020 I BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first participant in the global PHEARLESS Phase 1/2 study with BMN 307, an investigational gene therapy for the treatment of individuals with PKU. BMN 307 is an AAV5-phenylalanine hydroxylase (PAH) gene therapy designed to normalize blood phenylalanine (Phe) concentration levels in patients with PKU by inserting a correct copy of the PAH gene into liver cells. BMN 307 will be evaluated to determine safety and whether a single dose of treatment can restore natural Phe metabolism, normalize plasma Phe levels, and enable a normal diet in patients with PKU.

BioMarin will conduct this study with material manufactured with a commercial-ready process to facilitate rapid clinical development and potentially support approval. BMN 307 represents a potential third PKU treatment option in BioMarin's PKU franchise and a second gene therapy development program.

"More than 70 years ago, the first child was treated for PKU in the United Kingdom at Birmingham Women's and Children's Hospital. Today, we continue to make strides in PKU treatment through the clinical study of a gene therapy for PKU," said Tarekegn G. Hiwot at University Hospitals Birmingham NHS Foundation Trust and principal investigator for the PHEARLESS study. "There is a tremendous unmet need for PKU patients. As a treating physician, it is important to me to be involved in clinical research to evaluate innovative therapies that have the potential to change the treatment paradigm in PKU for good."

"BioMarin has been committed to the PKU community for more than 15 years and remains dedicated to the research and development of innovative therapies to advance the standard of care for people with PKU," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin. "Building upon our experience of delivering two approved PKU therapies to the PKU community, BMN 307 gene therapy combines BioMarin's leadership in the development of PKU therapies with our expertise in gene therapy development and manufacturing."

"PKU is a serious condition and many individuals struggle to manage their disorder on a daily basis. BioMarin is a pioneer in PKU treatments delivering the first two drug therapies to individuals with PKU. We applaud their unwavering commitment to drive research to bring a third treatment to the PKU community and for their substantial contributions to the overall body of scientific knowledge in PKU that they continue to make," said Christine S. Brown, MS, Executive Director, National PKU Alliance. "We are encouraged by BioMarin's efforts to develop a gene therapy that brings together their experience in PKU drug development, gene therapy development and gene therapy manufacturing. "

PKU is a rare genetic disease that manifests at birth and is marked by an inability to break down Phe, an amino acid that is commonly found in many foods. Left untreated, high levels of Phe become toxic to the brain and may lead to serious neurological and neuropsychological issues, affecting the way a person thinks, feels, and acts. Due to the seriousness of these symptoms, in many countries, infants are screened at birth to ensure early diagnosis and treatment to avoid intellectual disability and other complications. According to treatment guidelines, PKU patients should maintain lifelong control of their Phe levels.

Both the FDA and European Medicines Agency have granted BMN 307 Orphan Drug Designation. The Company is actively preparing regulatory submissions to open additional clinical sites in other countries.

BMN 307 Clinical Program

BioMarin's clinical program is composed of two key studies. PHEARLESS, a Phase 1/2 study, will evaluate the safety, efficacy, and tolerability of a single intravenous administration of BMN 307 in patients with PKU. The study consists of a dose-escalation phase, followed by a cohort expansion phase once an initially efficacious dose has been demonstrated. In addition, BioMarin is sponsoring an observational study, PHENOM, which includes patients with PKU to measure both established and new markers of disease and clinical outcomes over time.

BioMarin's 15-Plus Year Commitment to PKU Research

For more than 15 years, BioMarin has been a pioneer in ongoing research to help improve the lives of PKU patients. BioMarin has treated approximately 7,000 PKU patients around the world. The company has two approved PKU therapies, and the investigational gene therapy BMN 307 is currently in development. BioMarin has conducted 41 clinical studies in PKU and has sponsored 44 external clinical studies. BioMarin researchers have authored 65 publications in medical and scientific journals on PKU and supported another 57 publications by external researchers.

About Gene Therapy

Gene therapy is a form of treatment designed to address a genetic problem by adding a normal copy of the defective gene. The functional gene is inserted into a vector containing a small DNA sequence that acts as a delivery mechanism, providing the ability to deliver the functional gene to targeted cells. The cells can then use the information from the normal gene to build the functional proteins that the body needs, potentially reducing or eliminating the cause of the disease.

Gene Therapy Manufacturing

BioMarin has leveraged its knowledge and experience in manufacturing complex biological products to design, construct and validate a state-of-the-art vector production facility in Novato, California that was cGMP certified by the EMA in Q2 2020. This facility is the site of production for both valoctocogene roxaparvovec and BMN 307, investigational gene therapies. Manufacturing capabilities are an essential driver for BioMarin's gene therapy programs and allows the Company to control quality, capacity, costs and scheduling enabling rapid development. Production of BMN 307 with a commercial ready process at scale reduces risk associated with making process changes later in development and may speed overall development timelines significantly.

Ongoing process development efforts and experience gained at commercial scale have led to improvements in productivity and operational efficiency. The ability to scale out the facility with additional equipment combined with the improvements in productivity result in a doubling of overall potential capacity to 10,000 doses per year, combined for both products, depending on final dose and product mix. This improvement in productivity is anticipated to meet both commercial and clinical demand for both valoctocogene roxaparvovec and BMN 307 well into the future.

About Phenylketonuria

PKU, or phenylalanine hydroxylase (PAH) deficiency, is a genetic disorder affecting approximately 70,000 diagnosed patients in the regions of the world where BioMarin operates and is caused by a deficiency of the enzyme PAH. This enzyme is required for the metabolism of Phe, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe intellectual disability, seizures, tremors, behavioral problems and psychiatric symptoms. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all individuals with PKU under the age of 40 in countries with newborn screening programs are diagnosed at birth and treatment is implemented soon after. PKU can be managed with a severe Phe-restricted diet, which is supplemented by low-protein modified foods and Phe-free medical foods; however, it is difficult for most patients to adhere to the life-long strict diet to the extent needed to achieve adequate control of blood Phe levels. Dietary control of Phe in childhood can prevent major developmental neurological toxicities, but poor control of Phe in adolescence and adulthood is associated with a range of neurocognitive disabilities with significant functional impact.

To learn more about PKU and PAH deficiency, please visit http://www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases.The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.For additional information, please visitwww.biomarin.com. Information on such website is not incorporated by reference into this press release.

SOURCE: BioMarin Pharmaceutical

Continued here:
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy | DNA...

Read More...

Gene therapy company Taysha completes sprint from first funding to IPO – BioPharma Dive

Saturday, September 26th, 2020

Dive Brief:

Gene therapies have graduated from the laboratory bench to doctor's offices. The first wave of agents, Roche's Luxturna and Novartis' Zolgensma, are already altering the course of disease in two conditions, respectively an inherited form of blindness and the degenerative, often fatal disease spinal muscular atrophy.

In both cases those treatments were developed by companies that had relatively smaller pipelines, Spark Therapeutics for Luxturna and AveXis for Zolgensma.

Enter Taysha, which is headed by a former AveXis business development vice president, R.A. Session II. The company has highly ambitious hopes to launch a new product every two to three years, with the goal of building a durable business around adapting its technology across many diseases driven by defects in single genes.

The company also plans to build a commercial-scale manufacturing plant from the start, aiming to avoid some of the setbacks that can occur when production moves from facilities built to supply clinical trials.

The linchpin of the company's business is an agreement with UT-Southwestern, under which Taysha funds research and can obtain exclusive rights to experimental therapies for central nervous system disorders, through the end of 2021. Neurodegenerative disorders have proven challenging for some gene therapies because of the difficulties in delivering the viral vectors that carry gene replacements to brain tissue.

In spinning out Taysha, UT-Southwestern took an ownership stake in Taysha, amounting to 2.2 million shares, which is now worth more than $40 million. These ownership stakes have become more common with gene therapies in particular, as big pharma companies have been reluctant to license intellectual property straight out of university laboratories.

Taysha's lead project is called TSHA-101, which seeks to treat a condition called GM2 gangliosidosis, a disorder in which lipid accumulation destroys nerves in the brain and spinal cord. The first clinical trial is scheduled to begin in Canada by the end of 2020.

The company's shares rose following their first trades on the NASDAQ exchange, gaining 20% to close the day at $24.06.

Editor's note: This story was updated to reflect the share price at the close of trading.

Read more here:
Gene therapy company Taysha completes sprint from first funding to IPO - BioPharma Dive

Read More...

FDA sets back Novartis plans to expand use of SMA gene therapy – BioPharma Dive

Saturday, September 26th, 2020

Dive Brief:

Zolgensma's approval was a notable milestone, making it both the second gene therapy approved in the U.S., and the second treatment for SMA, a potentially deadly disease for which no medicines existed until four years ago.

But it's been a bumpy ride for Novartis since that 2019 approval. The FDA charged the company of manipulating preclinical data supporting its original application, a controversy that led Novartis to fire some top scientists and shake up its quality control operations. (The agency opted against sanctioning Novartis, however.)

And the drugmaker has now faced multiple delays in its effort to broaden the reach of Zolgensma beyond newborns and young infants.

That effort is crucial to the commercial prospects of Zolgensma. While SMA diagnosed in infancy, known as Type 1, is the most deadly, more people are living with the less severe forms of the disease. The nonprofit SMA foundation, for instance, estimates 88% of patients living with the disease have either Type 2 or Type 3, which can either stop people from walking or rob them of that ability later on.

Younger SMA patients need the muscle-boosting protein Zolgensma helps create to be expressed throughout the body, while older patients require a more targeted approach, which is why Novartis is developing the intrathecal version for them.

Currently, intravenous Zolgensma is approved in the U.S. and Japan for patients under two, and in Europe for children who weigh up to 21 kilograms. By comparison, Biogen's Spinraza and recently, Roche's Evrysdi are approved for much wider groups of SMA patients.

The intrathecal dose of Zolgensma is meant to even that playing field, though it may now be a few years until Novartis can bring that version to market.

The FDA initially halted testing of the intrathecal formulation in October, citing safety concerns from an animal study. That test is still on hold, but even when it restarts, Novartis will need more time to complete the new trial requested by the FDA. The company said the two developments are unrelated.

Novartis is discussing the details of the trial with the agency and said it will give a "comprehensive update" on its SMA program in the future. The pharma had been planning an approval submission next year, but Jefferies analyst Peter Welford now predicts that won't occur until at least 2023.

The delay boosts Roche's and Biogen's drugs, delaying would-be competition in older SMA patients. Novartis noted it's developing a similar type of drug to Roche's Evrysdi that's taken once a week orally.

Some 600 patients have been treated with Zolgensma through clinical trials, expanded access programs and commercially.

News of the FDA's request sent shares of gene therapy developer Regenxbio, which holds royalty rights to Zolgensma, down by as much as 9% Wednesday morning.

Excerpt from:
FDA sets back Novartis plans to expand use of SMA gene therapy - BioPharma Dive

Read More...

AVROBIO to Present at Two Upcoming Investor Conferences – Business Wire

Saturday, September 26th, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming virtual investor conferences.

Jefferies Virtual Gene Therapy/Editing SummitDate: Thursday, Oct. 1, 2020Time: 12:30 p.m. ET

Chardan Virtual 4th Annual Genetic Medicines ConferenceDate: Tuesday, Oct. 6, 2020Time: 2:00 p.m. ET

Live webcasts of the presentations will be available on the investors section of the AVROBIO website at avrobio.com. After the live webcasts, the events will remain archived on the AVROBIO website for 90 days.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward Looking Statement

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as aims, anticipates, believes, could, designed to, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks, will, and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our prospective product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, the expected benefits and results of our implementation of the plato platform in our clinical trials and gene therapy programs and the expected safety profile of our investigational gene therapies. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIOs current expectations, estimates and projections about our industry as well as managements current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIOs product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIOs product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our development timeline and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIOs actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled Risk Factors in AVROBIOs most recent Annual or Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIOs subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

See the original post:
AVROBIO to Present at Two Upcoming Investor Conferences - Business Wire

Read More...

Page 19«..10..18192021..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick